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REVIEW
Abstract: The two marine omega-3 fatty acids eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), prevalent in fish and fish oils, have been investigated as a
strategy towards prophylaxis of atherosclerosis. While the results with fish and fish oils have
been not as clear cut, the data generated with the purified ethyl ester forms of these two fatty
acids are consistent. Although slight differences in biological activity exist between EPA and
DHA, both exert a number of positive actions against atherosclerosis and its complications.
EPA and DHA as ethyl esters inhibit platelet aggregability, and reduce serum triglycerides,
while leaving other serum lipids essentially unaltered. Glucose metabolism has been studied
extensively, and no adverse effects were seen. Pro-atherogenic cytokines are reduced, as are
markers of endothelial activation. Endothelial function is improved, vascular occlusion is
reduced, and the course of coronary atherosclerosis is mitigated. Heart rate is reduced, and
heart rate variability is increased by EPA and DHA. An antiarrhythmic effect can be
demonstrated on the supraventricular and the ventricular level. More importantly, two large
studies showed reductions in clinical endpoints like sudden cardiac death or major adverse
cardiac events. As a consequence, relevant cardiac societies recommend using 1 g/day of EPA
and DHA for cardiovascular prevention, after a myocardial infarction and for prevention of
sudden cardiac death.
Keywords: sudden cardiac death, major adverse cardiac events, cardiovascular prevention,
eicosapentaenoic acid, docosahexaenoic acid
Introduction
Epidemiological data demonstrate an inverse relation between consumption of fish
and cardiovascular mortality and morbidity (von Schacky 2003). The active
ingredients in fish were presumed to be eicosapentaenoic (EPA) and docosahexaenoic
(DHA) acids, both omega-3 fatty acids found in fish (von Schacky 1987). A vast
number of studies have been performed, investigating effects and mechanisms of
these omega-3 fatty acids, especially with respect to cardiovascular prevention (von
Schacky 2003). The vast majority of these studies were performed with fish oils
containing various concentrations of EPA and DHA. Inherently, it was impossible to
differentiate between the effects of the other fatty acids present in the fish oils used
and EPA and DHA, let alone EPA versus DHA. In the early eighties, Mochida
pharmaceutical company in Japan developed a large scale method to purify EPA and
DHA in the chemical form of an ethyl ester. Subsequently, other companies, like
Pronova (previously known as Norsk Hydro), were also able to purify EPA and DHA
for use in humans. Since then, reports have appeared and keep appearing, investigating
isolated and combined EPA and DHA in the form of ethyl esters (von Schacky 2003).
This review focuses on these reports generated with EPA and/or DHA ethyl esters in
the cardiovascular area of interest. Since differences exist in the metabolism of fatty
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acids between experimental animals and humans, this review
will largely focus on studies reporting on data generated in
human studies with a few relevant animal investigations.
EPA and DHA have been studied jointly, as an 85% ethyl
ester concentrate of Norwegian provenience (unless
otherwise specified in this review: Omacor by Pronova). In
other studies, EPA or DHA were studied singly or separately
as ethyl esters (usually products by Mochida, Japan).
Method
Medline searches were conducted in March 2006 with the
terms: purified eicosapentaenoic acid, eicosapentaenoic acid
ethyl ester, eicosapentaenoic acid ethylester, ethyl
eicosapentaenoate, ethyl eicosapentaenoic, purified
docosahexaenoate, docosahexaenoic acid ethyl ester,
docosahexaenoic acid ethylester, ethyl docosahexaenoate,
ethyl docosahexaenoic, purified docosahexaenoic acid,
purified eicosapentaenoate, concentrated eicosapentaenoic,
concentrated docosahexaenoic, concentrated omega-3,
concentrated n-3, Omacor, and all publications with
cardiovascular topics were scrutinized. A Cochrane review
pertinent to the field was used as a source for publications
(Hooper et al 2004). Moreover, the author’s personal
database, generated during more than twenty years in the
field was used. Not all reports, however, clearly state in the
abstract, what chemical form of EPA and/or DHA was used,
which might have led to omission of a small number of
studies. Due to substantial disagreement over the correct
methodology, reports on ex vivo oxidizability or in vitro
work will not be reviewed.
Animal models
Largely, rats have been studied in animal investigations
using omega-3 fatty acids: In a metabolic study, EPA
appeared to inhibit intestinal cholesterol absorption and
hepatic cholesterol synthesis (Mizuguchi et al 1993).
Preliminary findings indicate that clearance of lipoproteins
from serum might be increased (Mizuguchi et al 1993). In a
model for non-insulin dependent diabetes mellitus, EPA
prevented insulin resistance (Mori et al 1997). Since an
increase in GLUT4 mRNA in skeletal muscle was found in
parallel, this was interpreted as an effect mediated by a
change in the fatty acid composition of the skeletal muscle
membrane (Mori et al 1997). In stroke-prone hypertensive
rats, EPA alleviated the age-dependent decrease in cerebral
blood flow and improved glucose utilization (Katayama et
al 1997). In salt-sensitive rats, EPA had no effect on
development of hypertension and obesity, and insulin
resistance was found to be less pronounced (Mori,
Murakawa, et al 1999). In male WBN/Kob rats, a model of
spontaneous diabetes, EPA dose-dependently prevented
development of diabetes and prevented insulin resistance
(Nobukata et al 2000a). Also, platelet response to adenosine
diphosphate and collagen was attenuated, and parameters
of blood coagulation were shifted towards a less
procoagulatory state (Nobukata et al 2000a). Moreover,
endothelial cell migration increased and smooth muscle cell
proliferation decreased (Nobukata et al 2000b). As compared
with safflower oil feeding, EPA-fed diabetes-prone rats were
leaner, had lower blood lipid levels, and a blunted insulin
response to glucose testing (Minami et al 2002). Another
study in the same rat model found platelet response to ADP
and collagen reduced, and a number of coagulation and
fibrinolysis parameters altered towards a less procoagulatory
state (Mori, Nobukata, et al 2003). Also, migration activity
of vascular endothelial cells was increased, and binding of
vascular endothelial cells to vascular endothelial cell growth
factor decreased (Mori, Nobukata, et al 2003). When EPA
and DHA were compared, both reduced platelet response
to collagen and subsequent formation of thromboxane A2
to a similar degree (Nieuwenhuys and Hornstra 1998).
One study using rabbits has been published, in which
hypercholesterolemic rabbits were treated either with a
statin, EPA, or both. Carotid intima-media thickness was
followed after sheathing with a cuff. EPA, but not
pravastatin, tended to prevent intimal thickening (p=0.058).
Combination treatment prevented intimal thickening to a
significant degree (Yano et al 1997).
In one study, dogs were subjected to experimental
myocardial infarction after 8 week supplementing with EPA.
Unsupplemented dogs served as controls. EPA reduced
infarct size and preserved contractile function, and the
authors concluded that this effect was brought about by
inhibition of neutrophil infiltration into and subsequently
less damage to the infarcted myocardium (Otsuji et al 1993).
Taken together, animal studies performed in Japan
largely in various rat models, were mainly aimed at testing
EPA as a possible treatment in type 2 diabetes, and showed
promising results.
Resorption in humans
When ingested by humans in the chemical form of
phospholipids or triglycerides, peak levels of EPA and DHA
in plasma are higher than when ingested as ethyl esters
(Beckermann et al 1990; Visioli et al 2003). There is some
debate as to whether this reflects better or faster absorptionVascular Health and Risk Management 2006:2(3) 253
Omega-3 ethyl esters in cardiovascular prevention
of EPA and DHA as phospholipids or as triglycerides or
whether it relates to a slower but equally effective absorption
of EPA and DHA as ethyl esters (Rupp et al 2004). It has
even been argued that a slower absorption leads to steadier
plasma levels, and better antiarrhythmic effects (Rupp et al
2004). When given in comparable amounts as ethyl ester or
as triglyceride, slight differences in fatty acid incorporation,
but no differences in effects on lipids, parameters of
hemostasis, or platelet function were observed (Hansen et
al 1993). In the author’s opinion, it is not clear whether
there exists a meaningful difference in resorption or in the
biological effects between ethyl ester or triglyceride forms
of EPA and DHA.
Studies in healthy volunteers
In a 4 week study in healthy volunteers, EPA decreased
platelet aggregability and whole blood viscosity (Terano et
al 1983). In our own 6 day randomized crossover study using
6 g/day of either EPA or DHA, both fatty acids were rapidly
absorbed and selectively incorporated into specific platelet
phospholipid fractions (von Schacky and Weber 1985).
Platelet response to collagen was reduced by both EPA and
DHA, whereas platelet response to ADP was only reduced
by DHA (von Schacky and Weber 1985). A 4 week study
using 0.9 g/day EPA found levels of beta-thromboglobulin
and pressor response to angiotensin II reduced (Yoshimura
et al 1987). A kinetic study using 3g/day of either EPA or
DHA found incorporation in plasma and cells of EPA to
plateau at 6 weeks, whereas it took DHA 18 weeks to reach
its peak (Marangoni et al 1993). Our own 6 week
randomized, observer-blind study in 14 volunteers
demonstrated mRNA levels of platelet-derived growth
factor-A and -B, as measured ex vivo after supplementation
of the volunteers diet with 7 g/day of EPA–DHA, to be
reduced (Kaminski et al 1993). Our subsequent study
demonstrated this effect to be due solely to EPA–DHA, and
not to other unsaturated fatty acids. Moreover, reductions
in monocyte chemoattractant protein-1 were observed
(Baumann et al 1999). In a 7 week double-blind study in a
total of 234 healthy men, 3.8 g/day EPA or 3.6 g/day DHA
decreased triglycerides by 21% and 26%, respectively, high-
density lipoprotein (HDL) increased by 0.06 mmol/l only
in the DHA group (Grimsgaard et al 1997). In a 4 week
study in 33 healthy persons, EPA, but not DHA, decreased
mean platelet volume, and raised platelet count (Park and
Harris 2002). DHA was studied in postmenopausal women
receiving (n=18) or not receiving (n=14) hormone
replacement therapy in a 4 week randomized crossover trial
(Stark and Holub 2004). DHA lowered triglycerides and
heart rate, and increased HDL in all women. Retroconversion
of DHA to EPA was less in the women using hormone
replacement therapy (Stark and Holub 2004).
In the studies mentioned in the preceding paragraph,
consistent data on fatty acid metabolism were reported: After
ingestion of purified EPA, blood levels of EPA increased.
After ingestion of purified DHA, blood levels of DHA
increased. No study using purified EPA found increases in
DHA, strongly arguing against EPA being metabolized to
DHA in large amounts. However, all studies with DHA
supplements found increases in EPA, strongly implying
retroconversion of DHA to EPA. After supplementation with
EPA, but not with DHA, levels in docosapentaenoic acid
increased. Identical data have also been reported from
patients (eg, Mori, Watts, et al 2000).
EPA and DHA lower human
triglyceride levels
EPA–DHA
As mentioned above, from studies in healthy volunteers, it
had already become clear that EPA and DHA lower blood
triglycerides. EPA and DHA combined in fish oil do so in a
dose-dependent manner (von Schacky 1987). These findings
have been amplified in patients with hypertriglycerdemia.
In twenty-two patients with coronary artery disease, 3.4 g/
day of EPA–DHA reduced triglycerides by 17% (Eritsland
et al 1989). A 50% ethyl ester concentrate of EPA–DHA
(“Himega”) was compared with a triglyceride-based fish
oil in 13 hypertriglyceridemic persons in a twelve week
randomized crossover study (Simons et al 1990). Both
preparations lowered triglycerides by 50% in doses of 2 g/
day or 4 g/day (Simons et al 1990). 3.4 g/day EPA–DHA,
but not alpha-linolenic acid or linoleic acid, lowered
triglycerides in a randomized 6 week study in
hypercholesterolemic men (Kestin et al 1990). Four g/day
of EPA–DHA were compared with corn oil in a 5–6 month
randomized study in 20 hypertriglyceridemic patients
undergoing coronary bypass grafting in mid-study (Nilsen
et al 1991). At end of study, plasma triglycerides were
reduced by 39% by EPA–DHA, a number of other
parameters related to bleeding were unchanged (Nilsen et
al 1991). A 10 week randomized study compared 5.1 g/day
EPA–DHA with 6 g/day corn oil in 156 persons (Bonaa et
al 1992). Triglycerides were reduced by 21% in the EPA–
DHA group, with calculations pointing towards EPA being
more effective (Bonaa et al 1992). In a randomized, double
blind 6 week study in 43 hypertensive persons 3.4 g/day ofVascular Health and Risk Management 2006:2(3) 254
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EPA–DHA reduced triglycerides by 21%, whereas the corn
oil control did not (Lungershausen et al 1994). Similar
findings were reported from a similar study (McKeone et al
1997). The same dose of the same preparations for 12 week
was tested in 57 persons in the same manner. Triglycerides
were reduced by 28% by EPA–DHA (Grundt et al 1995). In
40 patients with severe hypertriglyceridemia (500–2000 mg/
dL), 3.4 g/day EPA–DHA given for four months, reduced
triglycerides by 45%, as compared with the patients
randomized to placebo (Harris et al 1997). In a 6 month
randomized study in 935 persons with hypertriglyceridemia
and other cardiovascular risk factors, 1.7 g/day EPA–DHA
reduced hypertriglyceridemia (Sirtori et al 1998). In a
randomized study in 28 hypertriglyceredemic persons
comparing 3.4 g/day EPA–DHA with gemfibrozil, both
reduced triglycerides (Stalenhoef et al 2000). In 14 patients
with familial combined hyperlipidemia, 3.4 g/day EPA–
DHA lowered triglycerides by 44% in a randomized
crossover study (Eritsland et al 1996). In a randomized study
in 14 patients with familial combined hyperlipidemia, 3.4 g/
day EPA–DHA reduced triglycerides by 44%, whereas
placebo did not (Calabresi et al 2004).
Purified EPA and/versus DHA
In an open study, 2.7 g/day of EPA reduced triglycerides in
primary hypercholesterolemia (Nozaki et al 1992). In 141
postmenopausal mildly hypertriglyceridemic Japanese
women randomized to hormone replacement therapy +1.8g
EPA/day, EPA decreased triglycerides by 27% (Kurabayashi
et al 2000). In a randomized comparative trial with 3g/day
of either EPA or DHA in 49 normolipidemic persons, EPA
decreased triglycerides significantly, whereas DHA did not
(Rambjor et al 1996). In mildly dyslipidemic men, 4 g daily
of EPA or DHA for 6 weeks reduced triglycerides by 18%
and 20%, respectively (Mori, Burke, et al 2000). Similar
findings were reported in a randomized controlled 6 week
study comparing 4 g/day EPA with 4 g/day DHA in diabetic
patients with hypertension (Woodman et al 2002).
EPA–DHA + statins
In a randomized study comparing 3 g/day of EPA–DHA
(“Himega”) with 40 mg/day of pravastatin in 32 patients
for 6 weeks, EPA–DHA, but not pravastatin, reduced
triglycerides by 30%, whereas pravastatin lowered low-
density lipoprotein (LDL) (Contacos et al 1993).
Combination therapy combined the effects (Contacos et al
1993). In a 5 week randomized study in 41 persons with
combined hyperlipidemia, addition of 3.4 g/day EPA–DHA
further reduced triglycerides, when added to treatment with
20 mg simvastatin (Nordoy et al 1998). This effect was
observed as being more pronounced in the post-prandial
state (Nordoy et al 2000). In a similar 8 week study in 14
patients with familial combined hyperlipidemia,
triglycerides were lowered by 27%, as compared with
placebo (Calabresi et al 2000). In a randomized one-year
study in 59 simvastatin-treated coronary heart disease
patients, 3.4 g/day EPA–DHA lowered triglycerides by
20%–30%, whereas they remained stable in the corn oil-
treated controls (Durrington et al 2001). In a 6 week,
randomized, placebo-controlled, 2 x 2 factorial study in 52
men with visceral obesity, both 3.4 g/day EPA–DHA and
40 mg atorvastatin reduced triglycerides by some 25%, with
the effect being additive in the men treated with both (Chan
et al 2002).
The triglyceride lowering effect is also reported in some
of the studies with clinical endpoints, using the ethyl esters
of EPA and DHA, which are reported in more detail below.
In the SHOT trial, triglycerides were lowered from
175+99 mg/dL to 142+89 mg/dL (Eritsland et al 1996). In
the GISSI Prevenzione trial, triglycerides were lowered by
3.4% by 0.85 g/day EPA–DHA (GISSI 1999). In a smaller,
shorter Norwegian study, triglycerides were lowered by
18.56% by 1.7 g/day EPA–DHA (Nilsen et al 2001). A slight
effect was also seen in Japan EPA Lipid Intervention Study
(JELIS), conducted with EPA, a trial yet to be published.
Taken together, it has been proven beyond reasonable
doubt that EPA–DHA lower triglycerides in humans.
Reductions are greater when initial levels are higher.
Reductions are greater when triglyceride levels are measured
in the postprandial state than when measured in the fasting
state (eg, Nordoy et al 2000). The effect appears dose-
dependent, and does not wane over time. Combination
therapy with a statin appeared safe in these mechanistic
studies. Adding EPA–DHA to a statin adds to the
triglyceride-lowering effect of the statin. It is unclear at
present whether EPA lowers triglycerides more effectively
than DHA.
Effects on other serum lipids
The effects of fish oil on serum lipids are reviewed in (Harris
1996). A recent review details the effects of purified EPA or
DHA on serum lipids (Mori and Woodman 2006).
EPA–DHA
Total cholesterol has been found to be decreased or unaltered
(Eritsland et al 1989; Grundt et al 1995; Harris et al 1997;Vascular Health and Risk Management 2006:2(3) 255
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Nordoy et al 1998; Calabresi et al 2000; Durrington et al
2001). Rather consistently, LDL has been seen to be
increased (Simons et al 1990; Calabresi et al 2000;
Stalenhoef et al 2000) with a few exceptions (Chan et al
2002). This may be due to the fact that the more buoyant,
fast-floating LDL-subclasses increase, while the denser,
slow-floating LDL-subclasses decrease (Calabresi et al
2000; Stalenhoef et al 2000). The more buoyant LDL
subclasses are thought to be less atherogenic. HDL was
increased in some studies up to 15%, whereas in others it
remained unaltered (eg, Nordoy et al 1998; Durrington et
al 2001; Calabresi et al 2004), In one study, the increase
was due to an increase in HDL-2 after supplementation with
EPA–DHA (Calabresi et al 2004). Apolipoprotein A usually
increased when studied.
EPA and/versus DHA
In open studies, 1.8 g or 2.7 g EPA per day reduced
cholesterol (Nozaki et al 1992; Tsuruta et al 1996). In trials
comparing similar amounts of EPA to DHA, EPA, but not
DHA decreased total cholesterol slightly (Rambjor et al
1996; Grimsgaard et al 1997). In more recent comparative
studies, no effects of either EPA or DHA were seen on total
cholesterol, HDL, or LDL levels (Mori, Burke, et al 2000;
Woodman et al 2002). DHA, but not EPA, increased LDL
particle size (Mori, Burke, et al 2000; Woodman et al 2003b).
After either EPA or DHA no clear-cut effects on HDL were
demonstrated (Nozaki et al 1992; Rambjor et al 1996; Mori,
Burke, et al 2000; Woodman et al 2002).
Taken together, there appears to be some diversity as to
the effects of EPA–DHA on cholesterol, LDL, and HDL.
This may be due to the differences in the populations or
patients studied. However, since results obtained with EPA–
DHA versus results obtained with either EPA or DHA
diverge, there may be even other sources of heterogeneity.
They remain to be clarified.
Studies in patients using surrogate
endpoints
Glucose metabolism
In an eight week study using 900 mg/day or 1800 mg/day
EPA in 24 patients with non-insulin dependent diabetes
mellitus, glycemic control was not altered (Westerveld et al
1993). Microalbuminuria was reduced by 900 mg/day EPA
after three months, the effect being sustained after 12
months, but left glycemic control unaltered in non-insulin
dependent diabetes patients with nephropathy (Shimizu et
al 1995b). This effect was also seen in a similar study, using
1800 mg/day EPA in 115 patients for 4 weeks (Shimizu et
al 1995a). In 64 hyperlipidemic coronary artery patients,
glycemic control was unaltered after one year of 3.4 g/day
EPA–DHA (Durrington et al 2001). In a 6 week double blind
study, comparing 4 g each of EPA with DHA and with olive
oil in 59 hypertensive diabetics, both EPA and DHA
increased fasting glucose levels (by 1.40+0.29 mmol and
0.98+0.29 mmol respectively), but neither had an effect on
glycated hemoglobin, fasting insulin or C-peptide
(Woodman et al 2002). In a one-year study, partly double-
blind in 935 persons with hypertriglyceridemia and other
cardiovascular risk factors, 1.7 g/day EPA–DHA had no
effect on parameters of glucose metabolism (Sirtori et al
1998). Taken together, neither EPA–DHA nor EPA nor DHA
has a meaningful effect on glucose metabolism (Farmer et
al 2006).
Blood rheology
Erythrocyte deformability was not altered by 900 mg/day
or 1800 mg/day EPA for eight weeks (Westerveld et al 1993).
Inflammatory markers/cytokines
In a 6 week study in 59 hypertensive type 2 diabetics, 4 g/
day of EPA or DHA reduced oxidant stress, as assessed as
urinary F2 isoprostane excretion, but C-reactive protein,
interleukin-6 or tumor necrosis factor-α were unaltered,
relative to the olive oil treated controls (Mori, Woodman, et
al 2003). A similar picture emerged, when P-selectin and
interleukin 6 were studied after 0.85 g/day EPA–DHA (Lee
et al 2006). After a myocardial infarction 300 patients were
given either EPA–DHA or corn oil in a randomized one-
year study (Grundt et al 2003). Homocysteine was found to
be reduced in the EPA–DHA-treated patients, but E-selectin
and soluble intercellular adhesion molecule-1 were not
altered (Grundt et al 2003). In a 3 year randomized study
comparing dietary counseling with no counseling, both
+2.4 g/day EPA–DHA in 563 elderly men with long-standing
hyperlipidemia, dietary counseling and EPA–DHA both
reduced soluble intercellular adhesion molecule-1 and
soluble thrombomodulin (Hjerkinn et al 2005). Thus,
markers of inflammation like C-reactive protein remained
largely unaltered in patients with cardiovascular disorders,
while markers of endothelial activation appear to be reduced.
Hemostatic parameters
Ivy bleeding time was prolonged, but other hemostaseologic
parameters were not significantly altered, after four weeks
of 3.4 g/day EPA–DHA in 40 patients after myocardialVascular Health and Risk Management 2006:2(3) 256
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infarction (Smith et al 1989). Platelet activating factor-
induced platelet aggregation was reduced by 900 mg/day
EPA for eight weeks in patients with diabetes mellitus type
2, the effect being more pronounced after 1800 mg/day of
EPA (Westerveld et al 1993). Platelet aggregation as induced
by collagen or ADP was not found to be altered (Westerveld
et al 1993). Bleeding time increased in one study in coronary
artery patients (Eritsland et al 1989). Fibrinolytic activity,
as assessed by PAI activity levels, was found to be increased
by 1800 mg/day of EPA in patients with coronary artery
disease (Tsuruta et al 1996). After 3.4 g/day EPA–DHA, a
similar picture emerged (Nordoy et al 2000). In 59
hypertensive type 2 diabetics, 4 g/day of EPA and 4 g/day
DHA were compared with olive oil in a 6 week randomized,
double blind study (Woodman et al 2003a). DHA, but not
EPA reduced platelet response to collagen and associated
thromboxane A2 formation (Woodman et al 2003a). Other
parameters like fibrinolytic activity, or vascular function
were not found to differ after the three interventions
(Woodman et al 2003a). A three month randomized study
comparing 0.85 g/EPA–DHA with usual care in 77 post
myocardial infarction patients saw no differences in levels
of fibrinogen or D-Dimer. von Willebrand factor, however
increased (Lee et al 2006). Thus, by and large, the available
evidence indicates that EPA–DHA reduce platelet
aggregability, and have a slight anticoagulatory effect, both
evidenced in a prolonged bleeding time. DHA appears more
effective in terms of inhibition of platelet aggregability than
EPA. However, in patients on aspirin, as most cardiovascular
patients are, the effects are probably negligible.
Hemodynamic parameters
In hypertensive patients, fish oils reduced blood pressure
dose-dependently, with meaningful effects being achieved
only at high doses (von Schacky 2003). Animal studies
indicated that the blood pressure lowering ingredients are
EPA and DHA (cf, Mori, Bao, et al 1999). In humans, only
a limited number of studies have been performed with EPA
and DHA ethylesters: 3.4 g/day EPA–DHA were compared
with 9.2 g/day alpha-linolenic acid and to 14.3 g/day linoleic
acid in a 6 week randomized study in 33 normotensive men
(Kestin et al 1990). EPA–DHA, but no other intervention,
lowered blood pressure (Kestin et al 1990). A double blind
randomized cross-over trial in treated hypertensive patients
with 3.4 g/day EPA–DHA found systolic/diastolic blood
pressure to be reduced by 3.1/1.8 mm Hg after 6 weeks,
whereas corn oil had no effect (Lungershausen et al 1994).
In a randomized 12 week study using 3.4 g/day EPA–DHA
in 57 hyperlipidemic patients, blood pressure was reduced,
whereas it remained stable in the control patients using corn
oil (Grundt et al 1995). In 32 mildly hypertensive, but
otherwise healthy patients, 3.4 g/day EPA–DHA for 4
months lowered systolic/diastolic blood pressure, as
assessed by ambulatory 24 h recording by 6/5 mm Hg,
whereas olive oil had no effect in the controls (Prisco et al
1998). In a 7 week double-blind randomized study in 224
normotensive healthy men, 3.4 g/day EPA and DHA were
compared. DHA lowered resting heart rate by 2.2 beats per
minute (bpm), whereas EPA lowered it by 1.9 bpm. Heart
rate was unaltered in the control group (Grimsgaard et al
1998). In a subsample of 52 patients, diastolic filling of the
heart improved, as assessed by echocardiography
(Grimsgaard et al 1998). Interestingly, in a randomized 6
week study comparing 4 g/day of EPA to DHA and to olive
oil in 59 overweight mildly hyperlipidemic men, only DHA
reduced blood pressure (Mori, Bao, et al 1999). The
ambulatory blood pressure recordings of the persons having
ingested DHA were 5.8/3.3 (systolic/diastolic) mm Hg lower
than in the olive oil group, whereas EPA had no effect (Mori,
Bao, et al 1999). Moreover heart rate was reduced by DHA
(daytime −3.7+1.2 bpm, nighttime 2.9+1.2 bpm), whereas
EPA did not have an effect (Mori, Bao, et al 1999). In a
one-year randomized, double-blind study in 45 hypertensive
heart transplant recipients, 3.4 g/day EPA–DHA held blood
pressure constant, whereas it increased by 8+3/3+2 mm Hg
in the placebo-treated control group (Holm et al 2001).
Moreover, renal function was preserved in the group treated
with EPA–DHA (Holm et al 2001). Thus, there clearly is a
blood pressure lowering effect of EPA–DHA. Interestingly,
blood pressure is lowered by DHA, but not by EPA. The
same holds true for heart rate. The finding that diastolic
filling is improved within 7 weeks of EPA–DHA adds to
the rationale to perform studies in congestive heart failure,
where diastolic filling plays a major role.
Endothelial function
A small number of studies found endothelial function to be
improved after fish oil ingestion by humans (von Schacky
2003). Endothelial function can be assessed by ultrasound
tracking of the vasomotory activity of the brachial artery
after occlusion, a method called flow mediated dilatation
(FMD). The method calls for a positive control with
sublingual glyceryl trinitrate to achieve maximal dilatation.
This method was used in the three investigations with ethyl
esters of EPA and DHA. Using 3.4 g/day of EPA–DHA in
30 hypercholesterolemic persons for four months,Vascular Health and Risk Management 2006:2(3) 257
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endothelial function was improved, whereas it remained
stable in the controls, randomized to corn oil in this double-
blind study (Goodfellow et al 2000). Maximal vasodilatory
response was unaltered (Goodfellow et al 2000). Another
way of assessing endothelial function is a plethysmographic
approach, which calls for intraarterial infusion of vasoactive
substances like acetylcholine, norepinephrine, and
sometimes sodium nitroprusside in various dosages. A
randomized, double-blind design was also used to compare
4 g/day EPA with 4 g/day DHA and with 4 g/day olive oil
(control) in 59 overweight, mildly hyperlipidemic men
(Mori, Watts, et al 2000). In this study, DHA, but not EPA
improved the response to acetylcholine (Mori, Watts, et al
2000). DHA, however, improved the response to sodium
nitroprusside and attenuated the constrictory response to
norepinephrine (Mori, Watts, et al 2000). Olive oil had no
effect (Mori, Watts, et al 2000). It was concluded that
endothelium-independent mechanisms are responsible for
the blood pressure lowering effect of DHA (Mori, Watts, et
al 2000). In a randomized crossover trial for 6 weeks, using
FMD as a method to assess endothelial function, 20 children
with familial (combined) hyperlipidemia received 1.2 g/day
DHA (Engler et al 2004). Endothelial function improved,
but levels of total cholesterol, LDL, and HDL increased, as
compared with the National Cholesterol Education Panel
(NCEP)-II diet during the control period (Engler et al 2004).
Thus, whether tested with ultrasound or
plethysmographically, the available evidence indicates that
EPA–DHA improve endothelial function in patients with
cardiovascular disorders. When compared, DHA, but not
EPA, was found to be effective.
Studies in patients using
intermediate endpoints
Vascular occlusion
Neither as an ethyl ester nor as a triglyceride do EPA–DHA
affect the rate of restenosis after percutaneous coronary
angioplasty, as systematically reviewed in a meta-analysis
(Balk et al 2006). Whether EPA and/or DHA as an ethyl
ester have an effect on carotid intima-media thickness,
another popular intermediate endpoint, has not been studied
to the authors’ knowledge. A study in 39 patients with
coronary artery disease found a reduction in anginal attacks,
glyceryl trinitrate consumption, and an increase in exercised
time brought about by 10 g/day of a fish oil concentrate for
12 weeks, whereas the parameters remained basically stable
in the olive oil-treated controls (Salachas et al 1994).
Interestingly, however, a profound positive effect of 3.4 g/
day EPA–DHA on the patency of newly constructed
hemodialysis polytetrafluorethylene grafts was observed in
a randomized one-year study in 24 patients (Schmitz et al
2002). Patency was 75.6% in the 12 patients randomized to
EPA–DHA, but only 14.9% in the corn oil control group
(Schmitz et al 2002). Interestingly, venous outflow resistance
and systemic blood pressure were decreased (Schmitz et al
2002).
More importantly, however, a randomized trial in 610
patients undergoing coronary bypass surgery was performed
to assess the effect of 3.4 g/day of EPA–DHA on the one-
year patency of the anastomoses (Shunt Occlusion Trial
[SHOT]; Eritsland et al 1996). EPA and DHA increased in
serum phospholipids. In 95% of patients, angiography was
performed at one year. Considering distal vein graft
anastomoses, 27% were occluded in the intervention group,
while 33% were occluded in the control group (p=0.034).
43% of patients in the intervention group had a distal
anastomosis occluded, whereas the corresponding number
in the control group was 51% (p=0.05). The occlusion rate
of the considerably smaller number internal mammary artery
grafts was low, and remained unaffected by the treatments
studied (Eritsland et al 1996). Vein graft patency correlated
with the amounts of EPA–DHA present in serum
phospholipid fatty acids (Eritsland et al 1996).
Thus, as demonstrated in animal models (von Schacky
2003), EPA–DHA prevent occlusion of arterial grafts, be it
venous or polytetrafluorethylene. While EPA–DHA appear
not to have an effect on pain-free walking distance in patients
with peripheral arterial disease (Sommerfeldt and Hiatt
2004), they might be a promising approach to improve graft
patency in these patients after surgery.
Arrhythmia
Omega-3 fatty acids exert antiarrhythmic effects in humans.
These effects are assessed in various ways:
• By assessing heart rate variability, which can be done
with a 24 h electrocardiogram. It has been demonstrated
repeatedly that high heart rate variability is associated
with a low likelihood of sudden cardiac death. A number
of studies had already demonstrated, that fish oils
increase heart rate variability (Schmidt et al 2005). In a
crossover trial, 10 patients with coronary artery disease
were treated with either 3 g or 6 g per day EPA–DHA
(Villa et al 2002). The variance of the RR intervals from
electrocardiogram recordings increased after both doses
(not significantly so in the small group). The ratio of the
low to high frequency, an index of interaction betweenVascular Health and Risk Management 2006:2(3) 258
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sympathetic and vagal modulation, decreased
significantly after both doses, indicating reduced
sympathetic tone (Villa et al 2002). More recently, a
larger study was performed in 58 elderly nursing home
residents (Holguin et al 2005). The effects of 2 g/day
EPA–DHA were compared with 2 g/day of soy oil on
heart rate variability. The average time- and frequency-
domain parameters of heart rate variability increased
significantly during the six month intervention period
after EPA–DHA and after soy bean oil, with EPA–DHA
being more effective (Holguin et al 2005). Further
studies are under way (Pater et al 2003).
• By studying patients with implanted cardioverters/
defibrillators. These devices not only deliver electric
shocks in order to restore a regular rhythm, but first try
to resolve the arrhythmia by electrically stimulating the
heart. Since the devices have recording capabilities, read-
outs can be used to assess rhythm disturbances. This
approach has been used in Fish oil Against Arrhythmia
Trial (FAAT), a randomized, double-blind 12 month
study in 402 patients, using 2.6 g/day EPA–DHA (Leaf
et al 2005). This intervention increased the levels of EPA
and DHA in the red blood cells in the actively treated
group from 3.5+0.1% to 7.6+0.3%. There was a trend
toward a longer time to first action of the device because
of ventricular tachycardia or fibrillation (p=0.057), the
primary endpoint (Leaf et al 2005). When “probable
events” were included in the analysis (secondary
endpoint), the time to first event was significantly longer
in the actively treated group (relative risk [RR] 0.69,
95% confidence interval [CI] 0.49–0.97, p=0.033). The
picture became clearer, when only patients compliant
for 11 months were analyzed. Here, the RR was 0.62
(95% CI 0.39–0.97, p=0.034). The results were not as
clear-cut as expected because of a high non-compliance
rate in both groups: 36.5% in the EPA–DHA group
versus 34.2% in the control group, which left the
analyzable number of participants below the initially
estimated study size. Adverse events were evenly
distributed between the EPA–DHA group and the control
group (Leaf et al 2005). Another randomized study using
1.8 g/day EPA–DHA in a similar population of 200
patients saw an increase of EPA and DHA from 4.7% to
8.3% in the patients’ red blood cells (Raitt et al 2005).
In the intervention group, the time to first episode
(primary endpoint) was slightly shorter, the difference
being far from significant (p=0.19). It has been argued
that the initial levels of EPA and DHA in this study were
high enough to obscure any treatment effect (Leaf et al
2005), an argument consistent with the concept of the
omega-3 index (Harris and von Schacky 2004).
However, it has also been argued that the ventricular
tachycardias and fibrillations seen in these patients do
not have the same etiology as sudden death in persons
with acute myocardial infarction.
• In the early postoperative phase, new onset of atrial
fibrillation is the most common complication, eg,
observed in roughly 33% of patients undergoing
coronary bypass surgery (Calo et al 2005). In a trial in
160 patients, randomized to receiving either 1.7 g/day
EPA–DHA or usual care for at least 5 days before until
discharge (around day 7), new development of atrial
fibrillation was the primary endpoint (Calo et al 2005).
This occurred in 33.3% of the patients in the control
group, but only in 15.2% of the intervention group
(p=0.013). The hospital stay (secondary endpoint) was
shorter in the intervention group (7.3+2.1 days) than in
the control group (8.3+2.6 days) (p=0.017).
All studies using intermediate endpoints mentioned were
not of a size to observe differences in clinical events.
However, the omega-3 fatty acid preparations were usually
well tolerated, and serious events like death or major adverse
cardiac events tended to occur less frequently in the treated
groups (no formal meta-analysis performed).
Studies in patients with clinical
endpoints
A 1.5 year randomized, double-blind, study was performed
in 300 patients, recruited between the fourth and the eighth
day after a myocardial infarction (Nilsen et al 2001). 150
patients received 3.4 g/day EPA–DHA, 150 patients received
identical corn oil capsules. Although the intervention caused
the expected effects on triglycerides and HDL, a significant
difference in clinical endpoints was not observed (Nilsen et
al 2001). A primary endpoint was not defined for this study,
and therefore study size was not estimated. From a statistical
point of view, the study appears underpowered to assess an
effect of the intervention on clinical endpoints.
More importantly, a reduction of total mortality, mostly
driven by a reduction in sudden cardiac death, by ingestion
of 0.85 g/day EPA–DHA was demonstrated by the GISSI-
Prevenzione study (GISSI 1999; Marchioli et al 2002).
GISSI-Prevenzione was a randomized, open-label 3.5 year
study performed in Italy in 11 323 persons having survived
a myocardial infarction for a median of 16 days (GISSI 1999;
Marchioli et al 2002). A factorial design was used, sinceVascular Health and Risk Management 2006:2(3) 259
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vitamin E was also to be tested, but showed no effect. The
primary endpoint, a combination of death, non-fatal
myocardial infarction, and stroke was reduced by 10% or
15% (p=0.048 or p=0.008 respectively), depending on the
analysis (two-way or four-way). The secondary endpoints
of total mortality (20%) cardiovascular mortality (30%), and
sudden death (45%) were all highly significantly reduced
by the intervention (with confidence intervals less than 1),
but non-fatal myocardial infarctions were not (GISSI 1999;
Marchioli et al 2002). The intervention was safe, and only
gastrointestinal disturbances were reported as side-effects
in some 5% of participants. Time course analyses of the
occurrence of the clinical endpoints demonstrated
diverging curves, all favoring the intervention (Marchioli
et al 2002). Importantly, treatment effects could be
discerned early, eg, in the case of total mortality after 90
days (p=0.037, CI 0.59–0.97), or in the case of sudden
cardiac death after 120 days (p=0.048, CI 0.22–0.99).
Since the results were largely driven by the reduction in
sudden cardiac death, they were interpreted as an
antiarrhythmic effect of EPA–DHA, in keeping with the
studies mentioned above, and a previous trial showing a
similar result (Burr et al 1989). Less progression and more
regression of coronary lesions combined with fewer
unstable plaques, resulting in smaller myocardial
infarction would be a complementary explanation (von
Schacky 2003).
A randomized study to assess the effect of 1.8 g/day EPA
in 18 645 hypercholesterolemic persons was conducted in
Japan. The study design has been published (Yokoyama and
Origasea, 2003). Major adverse cardiac events were reduced
(presented as a late breaking clinical trial at the American
Heart Association meeting in November 2005). A final
publication, however, is pending.
In contrast to fish, the natural source of EPA and DHA,
ethyl ester preparations of EPA +/and DHA contain no
mercury. Mercury has been found to be associated with the
risk of myocardial infarction (Guallar et al 2002). Depending
on the amount of mercury present in the fish consumed
versus the amount of EPA and DHA present, mercury might
counteract the positive effect of EPA and DHA. This could
have contributed, among other factors, to the negative effect
of fish intake in a study conducted in men with angina (Burr
et al 2003). Therefore, the positive effects of EPA +/and
DHA can be discerned more clearly, when studied as ethyl
esters. This is also reflected by the results of a Cochrane
analysis (Hooper et al 2004). When the trials using fish are
removed from the analyses, a clear picture emerges in favor
of EPA +/and DHA.
Conclusion
While differences exist in the biological action between EPA
and DHA, there is no reason to think that one of the two
fatty acids is biologically inactive. Quite to the contrary; as
outlined above, both favorably act on lipid parameters, and
other parameters pertinent to atherosclerosis, while exerting
no negative effects on glucose metabolism (Table 1). A large
body of evidence demonstrates that many factors pertinent
to the development of atherosclerosis and its complications
are positively influenced by EPA and DHA as ethyl esters.
As reviewed here, these factors comprise, but are not limited
to triglycerides, platelet aggregation, hemostatic parameters,
blood pressure, and endothelial function. Moreover, EPA
and DHA have antiarrhythmic properties. In large scale
clinical studies, this translates into survival benefits for
patients after a myocardial infarction. Ongoing studies will
further clarify this picture. However, as of now, important
cardiac societies, like the American Heart Association or
the European Society for Cardiology recommend EPA and
DHA for prevention of sudden cardiac death, for the
treatment after a myocardial infarction and for
cardiovascular prevention (Kris-Etherton et al 2002; De
Backer et al 2003; Priori et al 2003; van der Werf et al 2003).
A clear cut recommendation to use ethyl esters of EPA and
DHA, however, has not been given.
Table 1 Effects of purified eicosapentaenoic and
docosahexaenoic acid, as observed in human studies, only
significant differences were considered for inclusion. Arrows
reflect semi-quantitatively the findings from the literature
EPA DHA
Triglycerides ↓↓ ↓↓ ↓↓ ↓↓ ↓↓ ↓↓ ↓↓ ↓↓ ↓↓ ↓↓
Cholesterol ↔↔
LDL ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑
HDL ↔? ↑ ↑ ↑ ↑ ↑?
platelet aggregability (↓ ↓ ↓ ↓ ↓) ↓ ↓ ↓ ↓ ↓
mean platelet volume ↓ ↓ ↓ ↓ ↓↔
blood pressure ↔ ↓ ↓ ↓ ↓ ↓
heart rate ↓ ↓ ↓ ↓ ↓ ↓↓ ↓↓ ↓↓ ↓↓ ↓↓
endothelial function ↔ ↑ ↑ ↑ ↑ ↑
glucose metabolism ↔↔
Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LDL,
low-density lipoprotein; HDL, high-density lipoprotein.
Note: Information sourced from von Schacky and Weber 1985; Nozaki et al
1992; Rambjor et al 1996; Grimsgaard et al 1997, 1998; Mori, Bao, et al 1999;
Mori, Burke, et al 2000; Mori, Watts, et al 2000; Woodman et al 2000, 2002,
2003a, 2003b; Park and Harris 2002; Mori and Woodman 2006.Vascular Health and Risk Management 2006:2(3) 260
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